Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2004 Nov;96(11):1445–1454.

Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment.

Olugbenga E Ayodele 1, C Olutayo Alebiosu 1, Babatunde L Salako 1
PMCID: PMC2568593  PMID: 15586648

Abstract

The earliest clinical evidence of diabetic nephropathy is microalbuminuria. Progression from microalbuminuria to overt nephropathy occurs in 20-40% within a 10-year period with approximately 20% of these patients progressing to end-stage renal disease. End-stage renal disease develops in 50% of type-1 diabetes patients with overt nephropathy within 10 years and in more than 75% by 20 years in the absence of treatment. In type-2 diabetes, a greater proportion of patients have microalbuminuria and overt nephropathy at or shortly after diagnosis of diabetes. The incidence of diabetes is increasing worldwide, with subsequent increase in the incidence of diabetic nephropathy. The risk factors identified in the development of DN from longitudinal and cross-sectional studies include race, genetic susceptibility, hypertension, hyperglycemia, hyperfiltration, smoking, advanced age, male sex, and high-protein diet. Treatment interventions in diabetic nephropathy include glycemic control, treatment of hypertension, hyperlipidemia, cessation of smoking, protein restriction, and renal replacement therapy. Multifactorial approach includes combined therapy targeting hyperglycemia, hypertension, microalbuminuria, and dyslipidemia.

Full text

PDF
1445

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abboud O. L., Osman E. M., Musa A. R. The aetiology of chronic renal failure in adult Sudanese patients. Ann Trop Med Parasitol. 1989 Aug;83(4):411–414. doi: 10.1080/00034983.1989.11812365. [DOI] [PubMed] [Google Scholar]
  2. Akinsola W., Odesanmi W. O., Ogunniyi J. O., Ladipo G. O. Diseases causing chronic renal failure in Nigerians--a prospective study of 100 cases. Afr J Med Med Sci. 1989 Jun;18(2):131–137. [PubMed] [Google Scholar]
  3. Arauz-Pacheco Carlos, Parrott Marian A., Raskin Philip, American Diabetes Association Treatment of hypertension in adults with diabetes. Diabetes Care. 2003 Jan;26 (Suppl 1):S80–S82. doi: 10.2337/diacare.26.2007.s80. [DOI] [PubMed] [Google Scholar]
  4. Arauz-Pacheco Carlos, Parrott Marian A., Raskin Philip. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002 Jan;25(1):134–147. doi: 10.2337/diacare.25.1.134. [DOI] [PubMed] [Google Scholar]
  5. Bakris G. L., Copley J. B., Vicknair N., Sadler R., Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov;50(5):1641–1650. doi: 10.1038/ki.1996.480. [DOI] [PubMed] [Google Scholar]
  6. Bakris G. L. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 May 1;112(9):707–708. doi: 10.7326/0003-4819-112-9-707. [DOI] [PubMed] [Google Scholar]
  7. Bakris G. L., Mangrum A., Copley J. B., Vicknair N., Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar;29(3):744–750. doi: 10.1161/01.hyp.29.3.744. [DOI] [PubMed] [Google Scholar]
  8. Bakris G. L., Williams M., Dworkin L., Elliott W. J., Epstein M., Toto R., Tuttle K., Douglas J., Hsueh W., Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep;36(3):646–661. doi: 10.1053/ajkd.2000.16225. [DOI] [PubMed] [Google Scholar]
  9. Bakris G., Viberti G., Weston W. M., Heise M., Porter L. E., Freed M. I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan;17(1):7–12. doi: 10.1038/sj.jhh.1001444. [DOI] [PubMed] [Google Scholar]
  10. Blüthner M., Schmidt S., Siffert W., Knigge H., Nawroth P., Ritz E. Increased frequency of G-protein beta 3-subunit 825 T allele in dialyzed patients with type 2 diabetes. Kidney Int. 1999 Apr;55(4):1247–1250. doi: 10.1046/j.1523-1755.1999.00399.x. [DOI] [PubMed] [Google Scholar]
  11. Brancati F. L., Whittle J. C., Whelton P. K., Seidler A. J., Klag M. J. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. JAMA. 1992 Dec 2;268(21):3079–3084. [PubMed] [Google Scholar]
  12. Brenner B. M., Cooper M. E., de Zeeuw D., Keane W. F., Mitch W. E., Parving H. H., Remuzzi G., Snapinn S. M., Zhang Z., Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861–869. doi: 10.1056/NEJMoa011161. [DOI] [PubMed] [Google Scholar]
  13. Chobanian Aram V., Bakris George L., Black Henry R., Cushman William C., Green Lee A., Izzo Joseph L., Jr, Jones Daniel W., Materson Barry J., Oparil Suzanne, Wright Jackson T., Jr The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 14;289(19):2560–2572. doi: 10.1001/jama.289.19.2560. [DOI] [PubMed] [Google Scholar]
  14. Cooper M. E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998 Jul 18;352(9123):213–219. doi: 10.1016/S0140-6736(98)01346-4. [DOI] [PubMed] [Google Scholar]
  15. Curb J. D., Pressel S. L., Cutler J. A., Savage P. J., Applegate W. B., Black H., Camel G., Davis B. R., Frost P. H., Gonzalez N. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996 Dec 18;276(23):1886–1892. [PubMed] [Google Scholar]
  16. Earle K., Viberti G. C. Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int. 1994 Feb;45(2):434–437. doi: 10.1038/ki.1994.56. [DOI] [PubMed] [Google Scholar]
  17. Fried L. F., Orchard T. J., Kasiske B. L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001 Jan;59(1):260–269. doi: 10.1046/j.1523-1755.2001.00487.x. [DOI] [PubMed] [Google Scholar]
  18. Gall M. A., Hougaard P., Borch-Johnsen K., Parving H. H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997 Mar 15;314(7083):783–788. doi: 10.1136/bmj.314.7083.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gambaro G., Cavazzana A. O., Luzi P., Piccoli A., Borsatti A., Crepaldi G., Marchi E., Venturini A. P., Baggio B. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992 Aug;42(2):285–291. doi: 10.1038/ki.1992.288. [DOI] [PubMed] [Google Scholar]
  20. Gambaro Giovanni, Kinalska Ida, Oksa Adrian, Pont'uch Peter, Hertlová Miluse, Olsovsky Jindrich, Manitius Jacek, Fedele Domenico, Czekalski Stanislaw, Perusicová Jindriska. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002 Jun;13(6):1615–1625. doi: 10.1097/01.asn.0000014254.87188.e5. [DOI] [PubMed] [Google Scholar]
  21. Gokal R., Mallick N. P. Peritoneal dialysis. Lancet. 1999 Mar 6;353(9155):823–828. doi: 10.1016/s0140-6736(98)09410-0. [DOI] [PubMed] [Google Scholar]
  22. Goldstein S. Beta-blockers in hypertensive and coronary heart disease. Arch Intern Med. 1996 Jun 24;156(12):1267–1276. [PubMed] [Google Scholar]
  23. Gudex C. M. Health-related quality of life in endstage renal failure. Qual Life Res. 1995 Aug;4(4):359–366. doi: 10.1007/BF01593889. [DOI] [PubMed] [Google Scholar]
  24. Hostetter T. H., Rennke H. G., Brenner B. M. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982 Mar;72(3):375–380. doi: 10.1016/0002-9343(82)90490-9. [DOI] [PubMed] [Google Scholar]
  25. Hostetter T. H., Troy J. L., Brenner B. M. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 1981 Mar;19(3):410–415. doi: 10.1038/ki.1981.33. [DOI] [PubMed] [Google Scholar]
  26. Hovind P., Rossing P., Tarnow L., Smidt U. M., Parving H. H. Progression of diabetic nephropathy. Kidney Int. 2001 Feb;59(2):702–709. doi: 10.1046/j.1523-1755.2001.059002702.x. [DOI] [PubMed] [Google Scholar]
  27. Humar A., Johnson E. M., Gillingham K. J., Sutherland D. E., Payne W. D., Dunn D. L., Wrenshall L. E., Najarian J. S., Gruessner R. W., Matas A. J. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation. 1998 Jan 27;65(2):229–234. doi: 10.1097/00007890-199801270-00015. [DOI] [PubMed] [Google Scholar]
  28. Ismail N., Becker B., Strzelczyk P., Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int. 1999 Jan;55(1):1–28. doi: 10.1046/j.1523-1755.1999.00232.x. [DOI] [PubMed] [Google Scholar]
  29. Jacobsen Peter, Andersen Steen, Jensen Berit R., Parving Hans-Henrik. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003 Apr;14(4):992–999. doi: 10.1097/01.asn.0000054495.96193.bf. [DOI] [PubMed] [Google Scholar]
  30. Jeffers B. W., Estacio R. O., Raynolds M. V., Schrier R. W. Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int. 1997 Aug;52(2):473–477. doi: 10.1038/ki.1997.355. [DOI] [PubMed] [Google Scholar]
  31. King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 Sep;21(9):1414–1431. doi: 10.2337/diacare.21.9.1414. [DOI] [PubMed] [Google Scholar]
  32. Klahr S. Is there still a role for a diet very low in protein, with or without supplements, in the management of patients with end-stage renal failure? Curr Opin Nephrol Hypertens. 1996 Jul;5(4):384–387. doi: 10.1097/00041552-199607000-00017. [DOI] [PubMed] [Google Scholar]
  33. Klein R., Klein B. E., Moss S. E., Cruickshanks K. J., Brazy P. C. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care. 1999 May;22(5):743–751. doi: 10.2337/diacare.22.5.743. [DOI] [PubMed] [Google Scholar]
  34. Knowler William C., Barrett-Connor Elizabeth, Fowler Sarah E., Hamman Richard F., Lachin John M., Walker Elizabeth A., Nathan David M., Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393–403. doi: 10.1056/NEJMoa012512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Krolewski A. S. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999 Apr;55(4):1582–1596. doi: 10.1046/j.1523-1755.1999.00371.x. [DOI] [PubMed] [Google Scholar]
  36. Kunz R., Bork J. P., Fritsche L., Ringel J., Sharma A. M. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol. 1998 Sep;9(9):1653–1663. doi: 10.1681/ASN.V991653. [DOI] [PubMed] [Google Scholar]
  37. Kuramoto N., Iizuka T., Ito H., Yagui K., Omura M., Nozaki O., Nishikawa T., Tsuchida H., Makino H., Saito Y. Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am J Kidney Dis. 1999 Feb;33(2):276–281. doi: 10.1016/s0272-6386(99)70300-8. [DOI] [PubMed] [Google Scholar]
  38. Kurokawa Kiyoshi, Nangaku Masaomi, Saito Akira, Inagi Reiko, Miyata Toshio. Current issues and future perspectives of chronic renal failure. J Am Soc Nephrol. 2002 Jan;13 (Suppl 1):S3–S6. [PubMed] [Google Scholar]
  39. Lam K. S., Cheng I. K., Janus E. D., Pang R. W. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. 1995 May;38(5):604–609. doi: 10.1007/BF00400731. [DOI] [PubMed] [Google Scholar]
  40. Levey A. S., Adler S., Caggiula A. W., England B. K., Greene T., Hunsicker L. G., Kusek J. W., Rogers N. L., Teschan P. E. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1996 May;27(5):652–663. doi: 10.1016/s0272-6386(96)90099-2. [DOI] [PubMed] [Google Scholar]
  41. Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., Ritz E., Atkins R. C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851–860. doi: 10.1056/NEJMoa011303. [DOI] [PubMed] [Google Scholar]
  42. Mallick N. P., Gokal R. Haemodialysis. Lancet. 1999 Feb 27;353(9154):737–742. doi: 10.1016/s0140-6736(97)09411-7. [DOI] [PubMed] [Google Scholar]
  43. Mogensen C. E. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999 Mar;42(3):263–285. doi: 10.1007/s001250051151. [DOI] [PubMed] [Google Scholar]
  44. Mogensen C. E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R. W., Cooper M. E. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000 Dec 9;321(7274):1440–1444. doi: 10.1136/bmj.321.7274.1440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Mulec H., Blohmé G., Grände B., Björck S. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant. 1998 Mar;13(3):651–655. doi: 10.1093/ndt/13.3.651. [DOI] [PubMed] [Google Scholar]
  46. Muntner Paul, He Jiang, Hamm Lee, Loria Catherine, Whelton Paul K. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002 Mar;13(3):745–753. doi: 10.1681/ASN.V133745. [DOI] [PubMed] [Google Scholar]
  47. Nakano S., Fukuda M., Hotta F., Ito T., Ishii T., Kitazawa M., Nishizawa M., Kigoshi T., Uchida K. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes. 1998 Sep;47(9):1501–1506. doi: 10.2337/diabetes.47.9.1501. [DOI] [PubMed] [Google Scholar]
  48. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 May;28(2):103–117. doi: 10.1016/0168-8227(95)01064-k. [DOI] [PubMed] [Google Scholar]
  49. Orth S. R., Ritz E., Schrier R. W. The renal risks of smoking. Kidney Int. 1997 Jun;51(6):1669–1677. doi: 10.1038/ki.1997.232. [DOI] [PubMed] [Google Scholar]
  50. Pan X. R., Li G. W., Hu Y. H., Wang J. X., Yang W. Y., An Z. X., Hu Z. X., Lin J., Xiao J. Z., Cao H. B. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537–544. doi: 10.2337/diacare.20.4.537. [DOI] [PubMed] [Google Scholar]
  51. Parving H. H., Andersen A. R., Smidt U. M., Svendsen P. A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983 May 28;1(8335):1175–1179. doi: 10.1016/s0140-6736(83)92462-5. [DOI] [PubMed] [Google Scholar]
  52. Peterson J. C., Adler S., Burkart J. M., Greene T., Hebert L. A., Hunsicker L. G., King A. J., Klahr S., Massry S. G., Seifter J. L. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995 Nov 15;123(10):754–762. doi: 10.7326/0003-4819-123-10-199511150-00003. [DOI] [PubMed] [Google Scholar]
  53. Pettitt D. J., Saad M. F., Bennett P. H., Nelson R. G., Knowler W. C. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990 Jul;33(7):438–443. doi: 10.1007/BF00404096. [DOI] [PubMed] [Google Scholar]
  54. Pugh J. A., Stern M. P., Haffner S. M., Eifler C. W., Zapata M. Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am J Epidemiol. 1988 Jan;127(1):135–144. doi: 10.1093/oxfordjournals.aje.a114773. [DOI] [PubMed] [Google Scholar]
  55. Ravid M., Neumann L., Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int. 1995 Mar;47(3):907–910. doi: 10.1038/ki.1995.135. [DOI] [PubMed] [Google Scholar]
  56. Reddi A. S., Camerini-Davalos R. A. Diabetic nephropathy. An update. Arch Intern Med. 1990 Jan;150(1):31–43. [PubMed] [Google Scholar]
  57. Reeves W. B., Andreoli T. E. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7667–7669. doi: 10.1073/pnas.97.14.7667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Remuzzi Giuseppe, Schieppati Arrigo, Ruggenenti Piero. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002 Apr 11;346(15):1145–1151. doi: 10.1056/NEJMcp011773. [DOI] [PubMed] [Google Scholar]
  59. Ritz E., Ogata H., Orth S. R. Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab. 2000 Jul;26 (Suppl 4):54–63. [PubMed] [Google Scholar]
  60. Ritz E., Orth S. R. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999 Oct 7;341(15):1127–1133. doi: 10.1056/NEJM199910073411506. [DOI] [PubMed] [Google Scholar]
  61. Ritz E., Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis. 1996 Feb;27(2):167–194. doi: 10.1016/s0272-6386(96)90538-7. [DOI] [PubMed] [Google Scholar]
  62. Rosner Mitchell H., Okusa Mark D. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med. 2003 May 12;163(9):1025–1029. doi: 10.1001/archinte.163.9.1025. [DOI] [PubMed] [Google Scholar]
  63. Rossing Kasper, Christensen Per K., Jensen Berit R., Parving Hans-Henrik. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002 Jan;25(1):95–100. doi: 10.2337/diacare.25.1.95. [DOI] [PubMed] [Google Scholar]
  64. Rossing P., Tarnow L., Boelskifte S., Jensen B. R., Nielsen F. S., Parving H. H. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes. 1997 Mar;46(3):481–487. doi: 10.2337/diab.46.3.481. [DOI] [PubMed] [Google Scholar]
  65. Salako B. L., Ayodele O. E., Kadiri S., Arije A. Prevalence of hepatitis B and C viruses in pre-dialysis patients with chronic renal failure. Afr J Med Med Sci. 2002 Dec;31(4):311–314. [PubMed] [Google Scholar]
  66. Salako B. L., Finomo F. O., Kadiri S., Arije A., Olatosin A. O. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy. Afr J Med Med Sci. 2002 Mar;31(1):53–57. [PubMed] [Google Scholar]
  67. Sawicki P. T., Siebenhofer A. Betablocker treatment in diabetes mellitus. J Intern Med. 2001 Jul;250(1):11–17. doi: 10.1046/j.1365-2796.2001.00829.x. [DOI] [PubMed] [Google Scholar]
  68. Seaquist E. R., Goetz F. C., Rich S., Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989 May 4;320(18):1161–1165. doi: 10.1056/NEJM198905043201801. [DOI] [PubMed] [Google Scholar]
  69. Shah V. O., Scavini M., Nikolic J., Sun Y., Vai S., Griffith J. K., Dorin R. I., Stidley C., Yacoub M., Vander Jagt D. L. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab. 1998 Aug;83(8):2886–2891. doi: 10.1210/jcem.83.8.5028. [DOI] [PubMed] [Google Scholar]
  70. Sowers J. R., Epstein M., Frohlich E. D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001 Apr;37(4):1053–1059. doi: 10.1161/01.hyp.37.4.1053. [DOI] [PubMed] [Google Scholar]
  71. Stegmayr B. G. A study of patients with diabetes mellitus (type 1) and end-stage renal failure: tobacco usage may increase risk of nephropathy and death. J Intern Med. 1990 Aug;228(2):121–124. doi: 10.1111/j.1365-2796.1990.tb00204.x. [DOI] [PubMed] [Google Scholar]
  72. Stewart Kerry J. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA. 2002 Oct 2;288(13):1622–1631. doi: 10.1001/jama.288.13.1622. [DOI] [PubMed] [Google Scholar]
  73. Tuomilehto J., Lindström J., Eriksson J. G., Valle T. T., Hämäläinen H., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343–1350. doi: 10.1056/NEJM200105033441801. [DOI] [PubMed] [Google Scholar]
  74. Velussi M., Brocco E., Frigato F., Zolli M., Muollo B., Maioli M., Carraro A., Tonolo G., Fresu P., Cernigoi A. M. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996 Feb;45(2):216–222. doi: 10.2337/diab.45.2.216. [DOI] [PubMed] [Google Scholar]
  75. Viberti Giancarlo, Wheeldon Nigel M., MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002 Aug 6;106(6):672–678. doi: 10.1161/01.cir.0000024416.33113.0a. [DOI] [PubMed] [Google Scholar]
  76. Wolfe R. A., Ashby V. B., Milford E. L., Ojo A. O., Ettenger R. E., Agodoa L. Y., Held P. J., Port F. K. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725–1730. doi: 10.1056/NEJM199912023412303. [DOI] [PubMed] [Google Scholar]
  77. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002 May 15;287(19):2563–2569. doi: 10.1001/jama.287.19.2563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Zeller K., Whittaker E., Sullivan L., Raskin P., Jacobson H. R. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991 Jan 10;324(2):78–84. doi: 10.1056/NEJM199101103240202. [DOI] [PubMed] [Google Scholar]
  79. Zoja Carla, Corna Daniela, Camozzi Davide, Cattaneo Dario, Rottoli Daniela, Batani Cristian, Zanchi Cristina, Abbate Mauro, Remuzzi Giuseppe. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002 Dec;13(12):2898–2908. doi: 10.1097/01.asn.0000034912.55186.ec. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES